InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Browse the detailed record of transactions filed by Boyle Kevin S. Sr., Chief Executive Officer. Director active across 1 companies, notably Ziopharm Oncology INC. Cumulatively, 4 reports have been published. Total volume traded: €2k. The latest transaction was filed on 16 November 2021 — Acquisition. Regulator: SEC (Form 4). All data is openly available.
Declarations4 total
€1,089884 shares@ €1.2317100.0% of flow
Common Stock
SEC:0001209191-21-065138·
Ideal exit: 13 Aug 2022 (T+270)
€1,089884 shares@ €1.231750.0% of flow
Common Stock
SEC:0001209191-21-065138:0·
Ideal exit: 13 Aug 2022 (T+270)
0875,000 shares0
Common Stock
SEC:0001209191-21-054089·
0875,000 shares0
Common Stock
SEC:0001209191-21-054089:0·
4 of 4 declarations
About Boyle Kevin S. Sr.
Kevin S. Boyle Sr. is the Chief Executive Officer of ZioPharm Oncology Inc. As CEO, he is responsible for the strategic direction of the company, overseeing operations and growth initiatives. His leadership is essential for the organization's success.
